596 results match your criteria Glioblastoma Multiforme* Neurology


Atypical Presentation of Glioblastoma Multiforme.

Eur J Case Rep Intern Med 2018 27;5(9):000954. Epub 2018 Sep 27.

Neurology Department, Henry Ford Health System, Detroit, MI, USA.

Background: Glioblastoma multiforme (GBM) is a highly malignant glial tumour classified by the World Health Organization (WHO) as a stage IV astrocytoma. It varies in shape and size and can be cystic, vascular and necrotic. It often appears as a ring-enhancing lesion on magnetic resonance imaging (MRI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346815PMC
September 2018
1 Read

Distribution of cancer stem cells in two human brain gliomas.

Oncol Lett 2019 Feb 12;17(2):2123-2130. Epub 2018 Dec 12.

Department of Neurosurgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.

There is compelling evidence that brain tumors, particularly glioblastoma multiforme (GBM), harbor a small population of cancer stem cells (CSCs). These CSCs have the ability to undergo self-renewal, initiate tumors , and are resistant to chemotherapy and radiation therapy. The present study determined the spatial distribution of CSCs within the donated brains of two deceased patients affected by glioblastoma multiforme. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2018.9824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351732PMC
February 2019

The Use of Recombinant Poliovirus for the Treatment of Recurrent Glioblastoma Multiforme.

World Neurosurg 2019 Jan 22. Epub 2019 Jan 22.

Department of Neurological Surgery, Mayo Clinic, Phoenix, Arizona; Precision Neuro-therapeutics Innovation Lab, Mayo Clinic, Phoenix, AZ; Neurosurgery Stimulation and Innovation Lab, Mayo Clinic, Phoenix, AZ; Department of Otolaryngology, Mayo Clinic, Phoenix, AZ; Department of Radiology, Mayo Clinic, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.01.050DOI Listing
January 2019
1 Read

Curcumin and Solid Lipid Curcumin Particles Induce Autophagy, but Inhibit Mitophagy and the PI3K-Akt/mTOR Pathway in Cultured Glioblastoma Cells.

Int J Mol Sci 2019 Jan 18;20(2). Epub 2019 Jan 18.

Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA.

Autophagy and the (PI3K-Akt/mTOR) signaling pathway play significant roles in glioblastoma multiforme (GBM) cell death and survival. Curcumin (Cur) has been reported to prevent several cancers, including GBM. However, the poor solubility and limited bioavailability of natural Cur limits its application in preventing GBM growth. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/2/399
Publisher Site
http://dx.doi.org/10.3390/ijms20020399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359162PMC
January 2019
9 Reads

Blockade of a laminin-411 - Notch axis with CRISPR/Cas9 or a nanobioconjugate inhibits glioblastoma growth through tumor-microenvironment crosstalk.

Cancer Res 2019 Jan 18. Epub 2019 Jan 18.

Department of Neurosurgery, Cedars-Sinai Medical Center

There is an unmet need for the treatment of glioblastoma multiforme (GBM). The extracellular matrix (ECM), including laminins, in the tumor microenvironment is important for tumor invasion and progression. In a panel of 226 patient brain glioma samples, we found a clinical correlation between the expression of tumor vascular laminin-411 (α4β1γ1) with higher tumor grade and with expression of cancer stem cell (CSC) markers including Notch pathway members, CD133, Nestin, and c-Myc. Read More

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-18-2725DOI Listing
January 2019
6 Reads

Comorbidities in elderly patients with glioblastoma: a field-practice study.

Future Oncol 2019 Jan 18. Epub 2019 Jan 18.

Neuro-Oncology Unit, 'Regina Elena' National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.

Aim: This single-center study evaluated the effect of comorbidities on progression-free and overall survival in elderly patients with glioblastoma multiforme (GBM).

Patients & Methods: Comorbid conditions were identified in each patient with the modified version of the cumulative illness rating scale (CIRS).

Results:  Total of 118 patients with GBM were enrolled. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0524
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0524DOI Listing
January 2019
5 Reads

Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma.

Int J Mol Sci 2019 Jan 8;20(1). Epub 2019 Jan 8.

Buddhist Tzu Chi Bioinnovation Center, Tzu Chi Foundation, Hualien 970, Taiwan.

Glioblastoma multiforme (GBM) is a type of brain tumor that is notorious for its aggressiveness and invasiveness, and the complete removal of GBM is still not possible, even with advanced diagnostic strategies and extensive therapeutic plans. Its dismal prognosis and short survival time after diagnosis make it a crucial public health issue. Understanding the molecular mechanisms underlying GBM may inspire novel and effective treatments against this type of cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20010200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337644PMC
January 2019
3 Reads
2.862 Impact Factor

Peptidylarginine Deiminases Post-Translationally Deiminate Prohibitin and Modulate Extracellular Vesicle Release and MicroRNAs in Glioblastoma Multiforme.

Int J Mol Sci 2018 Dec 28;20(1). Epub 2018 Dec 28.

Tissue Architecture and Regeneration Research Group, School of Life Sciences, University of Westminster, London W1W 6UW, UK.

Glioblastoma multiforme (GBM) is the most aggressive form of adult primary malignant brain tumour with poor prognosis. Extracellular vesicles (EVs) are a key-mediator through which GBM cells promote a pro-oncogenic microenvironment. Peptidylarginine deiminases (PADs), which catalyze the post-translational protein deimination of target proteins, are implicated in cancer, including via EV modulation. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/1/103
Publisher Site
http://dx.doi.org/10.3390/ijms20010103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337164PMC
December 2018
1 Read
2.862 Impact Factor

TRAF6 correlated to invasion and poor prognosis of glioblastoma via elevating MMP9 expression.

Neuroreport 2019 01;30(2):127-133

Department of Burn and Plastic Surgery, Qilu Hospital of Shandong University, Jinan, China.

Aberrant expression of tumor necrosis factor receptor-associated factor 6 (TRAF6) was reported in several types of cancers and it was demonstrated to promote tumor progression. In glioblastoma multiforme (GBM), TRAF6 depression by miRNA could decrease GBM cell resistance to temozolomide, but the prognostic values of TRAF6 and its functions in GBM progression have not been elucidated. In our study, the expression of TRAF6 and matrix metalloprotein 9 (MMP9) in 101 cases of GBM were investigated using immunohistochemistry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNR.0000000000001171DOI Listing
January 2019

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Acta Neuropathol Commun 2018 Dec 5;6(1):135. Epub 2018 Dec 5.

Activartis Biotech GmbH, Wilhelminenstraße 91/IIf, 1160, Vienna, Austria.

Audencel is a dendritic cell (DC)-based cellular cancer immunotherapy against glioblastoma multiforme (GBM). It is characterized by loading of DCs with autologous whole tumor lysate and in vitro maturation via "danger signals". The recent phase II "GBM-Vax" trial showed no clinical efficacy for Audencel as assessed with progression-free and overall survival in all patients. Read More

View Article

Download full-text PDF

Source
https://actaneurocomms.biomedcentral.com/articles/10.1186/s4
Publisher Site
http://dx.doi.org/10.1186/s40478-018-0621-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280511PMC
December 2018
10 Reads

Safety and efficacy of targeted alpha therapy with Bi-DOTA-substance P in recurrent glioblastoma.

Eur J Nucl Med Mol Imaging 2019 03 29;46(3):614-622. Epub 2018 Nov 29.

European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.

Treatment options for recurrent glioblastoma multiforme (GBM) are very limited. GBM cells express high levels of the GPCR neurokinin type 1 receptor (NK-1R), and a modified substance P can be used as its ligand for the tumor cell targeting. Targeted alpha therapy with DOTA-Substance P labeled with the short range alpha emitter Bi allows for selective irradiation and killing of tumor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4225-7DOI Listing
March 2019
10 Reads

Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.

Front Oncol 2018 13;8:521. Epub 2018 Nov 13.

Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation, Sylvester Comprehensive Cancer Center, Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, United States.

Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor. Despite aggressive multimodality treatment it remains one of the most challenging and intractable cancers (1]. While current standard of care treatment for GBM is maximal safe surgical resection, systemic chemotherapy with Temozolimide (TMZ), and radiation therapy, the current prognosis of GBM patients remains poor, with a median overall survival of 12-15 months (2, 3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00521DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243054PMC
November 2018
2 Reads

Effect of contrast agent dosage on longitudinal relaxation time, signal and apparent tumor volume in glioblastoma at 9.4T.

Z Med Phys 2018 Nov 20. Epub 2018 Nov 20.

University Hospital Heidelberg, Department of Neuroradiology, Germany.

Introduction: Glioblastoma multiforme is the most frequent innate brain tumor and still yields an unfavorable prognosis of 15 months of survival after diagnosis. Animal models play an important role in the investigation of therapeutic strategies of brain tumors. Thereby, MRI is substantial to individual follow-up examination for therapeutic response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.zemedi.2018.10.007DOI Listing
November 2018
10 Reads

EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis.

Mol Cancer 2018 11 23;17(1):166. Epub 2018 Nov 23.

Institute of Traumatic Brain Injury and Neurology, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, 300162, China.

Background: Circular RNAs (circRNAs) have been found to play critical roles in the development and progression of various cancers. However, little is known about the effects of the circular RNA network on glioblastoma multiforme (GBM).

Methods: A microarray was used to screen circRNA expression in GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0911-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260852PMC
November 2018
14 Reads

Variation in management of spinal gliobastoma multiforme: results from a national cancer registry.

J Neurooncol 2019 Jan 20;141(2):441-447. Epub 2018 Nov 20.

Mayo Clinic Neuro-Informatics Laboratory, Mayo Clinic College of Medicine and Science, Rochester, MN, 55902, USA.

Purpose: Primary glioblastoma of the spinal cord (spinal GBM) is a rare central nervous system tumor, relative to its cranial counterpart (cranial GBM). Our current knowledge of spinal GBM epidemiology, tumor characteristics and treatment are insufficient and mostly based on single-institution case series.

Methods: All patients diagnosed with grade-4 GBM from 2004 to 2014 were queried from the National Cancer Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-03054-2DOI Listing
January 2019
8 Reads

Autophagy induction impairs Wnt/β-catenin signalling through β-catenin relocalisation in glioblastoma cells.

Cell Signal 2019 Jan 26;53:357-364. Epub 2018 Oct 26.

Department of Biosciences and Territory, University of Molise, Pesche, IS, Italy. Electronic address:

Autophagy is an evolutionary conserved process mediating lysosomal degradation of cytoplasmic material. Its involvement in cancer progression is highly controversial, due to its dual role in both limiting tumoural transformation and in protecting established tumoral cells from unfavorable conditions. Little is known about the cross-talk between autophagy and intracellular signalling pathways, as well as about autophagy impact on signalling molecules turnover. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08986568183026
Publisher Site
http://dx.doi.org/10.1016/j.cellsig.2018.10.017DOI Listing
January 2019
18 Reads

An Adult Drosophila Glioma Model for Studying Pathometabolic Pathways of Gliomagenesis.

Mol Neurobiol 2018 Oct 24. Epub 2018 Oct 24.

Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, 114, Taiwan.

Glioblastoma multiforme (GBM), the most prevalent brain tumor in adults, has extremely poor prognosis. Frequent genetic alterations that activate epidermal growth factor receptor (EGFR) and phosphatidylinositol-3 kinase (PI3K) signaling, as well as metabolic remodeling, have been associated with gliomagenesis. To establish a whole-animal approach that can be used to readily identify individual pathometabolic signaling factors, we induced glioma formation in the adult Drosophila brain by activating the EGFR-PI3K pathway. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12035-018-1392-2
Publisher Site
http://dx.doi.org/10.1007/s12035-018-1392-2DOI Listing
October 2018
14 Reads

Identification of a panel of genes as a prognostic biomarker for glioblastoma.

EBioMedicine 2018 Nov 16;37:68-77. Epub 2018 Oct 16.

Department of Neurosurgery, Baylor Scott & White Health, Temple, TX 76502, USA; Neuroscience Institute, Baylor Scott & White Health, Temple, TX 76502, USA; Department of Surgery, Texas A & M Health Science Center, College of Medicine, Temple, TX 76508, USA; LIVESTRONG Cancer Institutes, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA; Department of Pharmaceutical Sciences, Texas A & M Health Science Center, College of Pharmacy, College Station, TX 77843, USA. Electronic address:

Background: Glioblastoma multiforme (GBM) is a fatal disease without effective therapy. Identification of new biomarkers for prognosis would enable more rational selections of strategies to cure patients with GBM and prevent disease relapse.

Methods: Seven datasets derived from GBM patients using microarray or next generation sequencing in R2 online database (http://r2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.10.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284420PMC
November 2018
2 Reads

PET imaging of intra-arterial Zr bevacizumab in mice with and without osmotic opening of the blood-brain barrier: distinct advantage of intra-arterial delivery.

J Nucl Med 2018 Oct 12. Epub 2018 Oct 12.

Johns Hopkins University School of Medicine, United States.

Glioblastoma multiforme (GBM) is the most aggressive and common type of brain cancer. Five-year survival rates are below 12%, even with the most aggressive tri-modal therapies. Poor blood-brain barrier (BBB) permeability of therapeutics is a major obstacle limiting efficacy. Read More

View Article

Download full-text PDF

Source
http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.218
Publisher Site
http://dx.doi.org/10.2967/jnumed.118.218792DOI Listing
October 2018
6 Reads

Impact of gender on the survival of patients with glioblastoma.

Biosci Rep 2018 Dec 7;38(6). Epub 2018 Nov 7.

Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, P.R. China

Preclinical models have suggested a role for sex hormones in the development of glioblastoma multiforme (GBM). However, the impact of gender on the survival time of patients with GBM has not been fully understood. The objective of the present study was to clarify the association between gender and survival of patients with GBM by analyzing population-based data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BSR20180752DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239255PMC
December 2018

Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule.

Cell Death Discov 2018 26;4:41. Epub 2018 Sep 26.

1Department of Pharmacology and Therapeutics, McGill University, Montreal, QC Canada.

Glioblastoma multiforme is one of the most aggressive brain tumors and current therapies with temozolomide or suberoylanilide hydroxamic acid (SAHA, vorinostat) show considerable limitations. SAHA is a histone deacetylase (HDAC) inhibitor that can cause undesirable side effects due to the lack of selectivity. We show here properties of a novel hybrid molecule, sahaquine, which selectively inhibits cytoplasmic HDAC6 at nanomolar concentrations without markedly suppressing class I HDACs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41420-018-0103-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158288PMC
September 2018

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.

Cancers (Basel) 2018 Oct 5;10(10). Epub 2018 Oct 5.

Clinical Division of Medical Oncology, Department for Internal Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

Dendritic cells (DCs) are antigen-presenting cells that are capable of priming anti-tumor immune responses, thus serving as attractive tools to generate tumor vaccines. In this multicentric randomized open-label phase II study, we investigated the efficacy of vaccination with tumor lysate-charged autologous DCs (Audencel) in newly diagnosed glioblastoma multiforme (GBM). Patients aged 18 to 70 years with histologically proven primary GBM and resection of at least 70% were randomized 1:1 to standard of care (SOC) or SOC plus vaccination (weekly intranodal application in weeks seven to 10, followed by monthly intervals). Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/10/10/372
Publisher Site
http://dx.doi.org/10.3390/cancers10100372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210090PMC
October 2018
4 Reads

Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme.

Asian J Neurosurg 2018 Jul-Sep;13(3):546-554

Metrohealth Medical Center, Case Western Reserve University School of Medicine, OH, USA.

Glioblastoma multiforme (GBM) has the highest rate of vascular proliferation among solid tumors. Angiogenesis is the central feature of rapid tumor growth in GBM and therefore remains an appealing therapeutic target in the treatment of these highly malignant tumors. Antiangiogenic therapy is emerging as an important adjuvant treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ajns.AJNS_266_16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159033PMC
October 2018
1 Read

Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.

World Neurosurg 2018 Dec 22;120:442-447. Epub 2018 Sep 22.

Department of Neurosurgery, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.

Background: Glioblastoma multiforme (GBM) is usually characterized by diffuse, infiltrative growth and local tumor progression. Extensive leptomeningeal metastases are rarely observed. It is unclear which GBMs are prone to this specific growth pattern and progression, and standardized salvage treatment protocols are unavailable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.09.082DOI Listing
December 2018
8 Reads

HMGB3 promotes the proliferation and metastasis of glioblastoma and is negatively regulated by miR-200b-3p and miR-200c-3p.

Cell Biochem Funct 2018 Oct 19;36(7):357-365. Epub 2018 Sep 19.

Department of Neurology, Daqing Oilfield General Hospital, Daqing, China.

High mobility group box 3 (HMGB3) is strongly involved in oncogenesis in a variety of cancers. In the present study, we have explored the role of HMGB3 in glioblastoma multiforme (GBM) tumorigenesis and have identified the microRNAs (miRNAs) miR-200b-3p and miR-200c-3p as negative regulators of HMGB3 expression. We began by determining that endogenous HMGB3 expression levels were significantly elevated in GBM tissues and in 3 GBM cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cbf.3355DOI Listing
October 2018

Frontal Tumefactive Demyelinating Lesion Mimicking Glioblastoma Differentiated by Methionine Positron Emission Tomography.

World Neurosurg 2018 Nov 13;119:244-248. Epub 2018 Aug 13.

Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu City, Japan.

Background: Tumefactive demyelinating lesion (TDL) is often reported as a rare variation of multiple sclerosis (MS). TDL is difficult to diagnose solely by magnetic resonance imaging (MRI) in patients with no history of MS. This is because the lesion often shows ring enhancement with perifocal brain edema on gadolinium MRI, thus mimicking glioblastoma multiforme (GBM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.08.027DOI Listing
November 2018
13 Reads

Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.

Cancer Lett 2018 Nov 10;436:10-21. Epub 2018 Aug 10.

Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Electronic address:

Chemoresistance blunts the effect of Temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM). Whether exosomal transfer of miRNAs derived from TMZ-resistant GBM cells could confer TMZ resistance remains to be determined. qPCR was used to determine miR-151a expression in two TMZ-resistant GBM cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2018.08.004DOI Listing
November 2018
7 Reads

The Expanding Role of Ketogenic Diets in Adult Neurological Disorders.

Brain Sci 2018 Aug 8;8(8). Epub 2018 Aug 8.

Department of Neurology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Meyer 2-147, Baltimore, MD 21287, USA.

The current review highlights the evidence supporting the use of ketogenic diet therapies in the management of adult epilepsy, adult malignant glioma and Alzheimer's disease. An overview of the scientific literature, both preclinical and clinical, in each area is presented and management strategies for addressing adverse effects and compliance are discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/brainsci8080148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119973PMC
August 2018
2 Reads

Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.

Eur J Nucl Med Mol Imaging 2018 12 21;45(13):2404-2412. Epub 2018 Jul 21.

Department of Medical Oncology, University of Groningen, University Medical Centre Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.

Purpose: Response evaluation in patients with glioblastoma after chemoradiotherapy is challenging due to progressive, contrast-enhancing lesions on MRI that do not reflect true tumour progression. In this study, we prospectively evaluated the ability of the PET tracer F-fluorothymidine (FLT), a tracer reflecting proliferative activity, to discriminate between true progression and pseudoprogression in newly diagnosed glioblastoma patients treated with chemoradiotherapy.

Methods: FLT PET and MRI scans were performed before and 4 weeks after chemoradiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4090-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208814PMC
December 2018
9 Reads

Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status.

Cancer Med 2018 Aug 15;7(8):3722-3742. Epub 2018 Jul 15.

Department of Neurology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.

The relationship between marital status and glioblastoma multiforme (GBM) has not been addressed in depth. Here, we aimed to investigate the association between marital status and survival in GBM. We searched the Surveillance, Epidemiology, and End Results (SEER) database and extracted the data of eligible patients diagnosed with GBM after 2004. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.1688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089174PMC
August 2018
4 Reads

"Micromanaging" Glioblastoma Multiforme: The Potential of MicroRNAs, Circular RNAs, and the Hippo Pathway as Novel Treatment Strategies.

Authors:
Kenneth Maiese

Curr Neurovasc Res 2018 ;15(3):173-174

Neurology and Neurosciences UMDNJ 205 South Orange Avenue, F1220 Newark, NJ 07101, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1567202615999180711123907DOI Listing
January 2018
2 Reads

Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles.

Oncotarget 2018 Jun 15;9(46):28083-28102. Epub 2018 Jun 15.

Centre for Cancer Research (CIC IBMCC-CSIC/USAL), Department of Medicine, CIBERONC, University of Salamanca, Salamanca, Spain.

Several classification systems have been proposed to address genomic heterogeneity of glioblastoma multiforme, but they either showed limited prognostic value and/or are difficult to implement in routine diagnostics. Here we propose a prognostic stratification model for these primary tumors based on tumor gene amplification profiles, that might be easily implemented in routine diagnostics, and potentially improve the patients management. Gene amplification profiles were prospectively evaluated in 80 primary glioblastoma multiforme tumors using single-nucleotide polymorphism arrays and the results obtained validated in publicly available data from 267/347 cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25562DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021328PMC
June 2018
5 Reads

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.

Front Immunol 2018 29;9:727. Epub 2018 May 29.

Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.

Background: Glioblastoma (GBM) is the most common and lethal primary malignant glioma in adults. Dendritic cell (DC) vaccines have demonstrated promising results in GBM clinical trials. However, some patients do not respond well to DC therapy, with survival rates similar to those of conventional therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.00727DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992384PMC
May 2018
41 Reads

Zeb1 potentiates genome-wide gene transcription with Lef1 to promote glioblastoma cell invasion.

EMBO J 2018 Aug 14;37(15). Epub 2018 Jun 14.

Molecular Neurobiology Laboratory, Instituto Gulbenkian de Ciência, Oeiras, Portugal

Glioblastoma is the most common and aggressive brain tumor, with a subpopulation of stem-like cells thought to mediate its recurring behavior and therapeutic resistance. The epithelial-mesenchymal transition (EMT) inducing factor Zeb1 was linked to tumor initiation, invasion, and resistance to therapy in glioblastoma, but how Zeb1 functions at molecular level and what genes it regulates remain poorly understood. Contrary to the common view that EMT factors act as transcriptional repressors, here we show that genome-wide binding of Zeb1 associates with both activation and repression of gene expression in glioblastoma stem-like cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15252/embj.201797115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068449PMC
August 2018
4 Reads

Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.

J Neurooncol 2018 Sep 7;139(3):731-738. Epub 2018 Jun 7.

Neuroinnovation Program, Multiple Sclerosis & Neuroimmunology Imaging Program, Department of Neurology & Neurotherapeutics, UT Southwestern Medical Center, Clinical Center for Multiple Sclerosis, 5323 Harry Hines Blvd., Dallas, TX, 75390-8806, USA.

Purpose: Pseudoprogression is often indistinguishable from true tumor progression on conventional 2-dimensional (2D) MRI in glioblastoma multiforme (GBM) patients. The aim of this study was to determine the association between post-gadolinium 3-dimensional (3D) characteristics and clinical state in GBM patients.

Methods: Standardized 3D brain MRI studies were performed, and contrast enhancing portions of each tumor were segmented and analyzed, blinded to clinical state, using principal component analysis (PCA), medial axis transformation (MAT), and coverage analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-018-2920-7DOI Listing
September 2018
3 Reads

Crizotinib and erlotinib inhibits growth of c-Met/EGFRvIII primary human glioblastoma xenografts.

Clin Neurol Neurosurg 2018 Aug 9;171:26-33. Epub 2018 Mar 9.

Department of Neurology, The Hugo W. Moser Research Institute at Kennedy Krieger Inc., United States; Department of Neurosurgery, The Johns Hopkins University, School of Medicine, Baltimore, MD, United States.

Objectives: Receptor tyrosine kinases (RTK), such as c-Met and epidermal growth factor receptor (EGFR), are implicated in the malignant progression of glioblastoma. Studies show that RTK systems can co-modulate distinct and overlapping oncogenic downstream signaling pathways. EGFRvIII, a constitutively activated EGFR deletion mutant variant, leads to increased tumor growth and diminishes the tumor growth response to HGF: c-Met pathway inhibitor therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2018.02.041DOI Listing
August 2018
6 Reads

A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.

Trials 2018 May 25;19(1):293. Epub 2018 May 25.

Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Hospital, Moorenstr. 5, 40225, Düsseldorf, Germany.

Background: Despite the combination of surgical resection, radio- and chemotherapy, median survival of glioblastoma multiforme (GBM) patients only slightly increased in the last years. Disease recurrence is definite with no effective therapy existing after tumor removal. Dendritic cell (DC) vaccination is a promising active immunotherapeutic approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-018-2659-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970474PMC
May 2018
4 Reads

Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.

Curr Med Chem 2018 May 13. Epub 2018 May 13.

Department of Neurology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiang West Road, Guangzhou, 510120. China.

Glioblastoma multiforme (GBM) is the most frequent glioma with a poor prognosis. The mainstay treatment for GBM is chemotherapy, but the average survival of GBM remains unsatisfactory due to therapeutic resistance. Poor permeability restricted by the blood brain barrier (BBB) and the presence of glioblastoma stem cells (GSCs) remain as two problems for chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867325666180514113136DOI Listing
May 2018
6 Reads

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Int J Radiat Oncol Biol Phys 2018 Apr 6;100(5):1195-1203. Epub 2018 Jan 6.

Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. Electronic address:

Purpose: To assess the safety and efficacy of upfront treatment using bortezomib combined with standard radiation therapy (RT) and temozolomide (TMZ), followed by adjuvant bortezomib and TMZ for ≤24 cycles, in patients with newly diagnosed glioblastoma multiforme (GBM).

Methods And Materials: Twenty-four patients with newly diagnosed GBM were enrolled. The patients received standard external beam regional RT with concurrent TMZ beginning 3 to 6 weeks after surgery, followed by adjuvant TMZ and bortezomib for ≤24 cycles or until tumor progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277207PMC
April 2018
16 Reads

The value of whole lesion ADC histogram profiling to differentiate between morphologically indistinguishable ring enhancing lesions-comparison of glioblastomas and brain abscesses.

Oncotarget 2018 Apr 6;9(26):18148-18159. Epub 2018 Apr 6.

Department for Neuroradiology, University Hospital Leipzig, Leipzig, Germany.

Background: Morphologically similar appearing ring enhancing lesions in the brain parenchyma can be caused by a number of distinct pathologies, however, they consistently represent life-threatening conditions. The two most frequently encountered diseases manifesting as such are glioblastoma multiforme (GBM) and brain abscess (BA), each requiring disparate therapeutical approaches. As a result of their morphological resemblance, essential treatment might be significantly delayed or even ommited, in case results of conventional imaging remain inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915063PMC
April 2018
7 Reads

Relapse pathway of glioblastoma revealed by single-cell molecular analysis.

Carcinogenesis 2018 07;39(7):931-936

Division of Periodontology, Diagnostic Sciences and Dental Hygiene, and Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.

Glioblastoma multiforme (GBM) remains an incurable brain tumor. The highly malignant behavior of GBM may, in part, be attributed to its intraclonal genetic and phenotypic diversity (subclonal evolution). Identifying the molecular pathways driving GBM relapse may provide novel, actionable targets for personalized diagnosis, characterization of prognosis and improvement of precision therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgy052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248540PMC
July 2018
7 Reads
5.334 Impact Factor

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with Bi-substance P analogue.

Eur J Nucl Med Mol Imaging 2018 07 30;45(9):1636-1644. Epub 2018 Apr 30.

European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, Germany.

Background: Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently as a secondary glial neoplasm. GBM has been demonstrated to overexpress the NK-1 receptor and substance P can be used as a ligand for targeted therapy. Alpha emitters, e. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-018-4015-2
Publisher Site
http://dx.doi.org/10.1007/s00259-018-4015-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061489PMC
July 2018
24 Reads

Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.

Cancer Lett 2018 Aug 27;428:77-89. Epub 2018 Apr 27.

Department of Interventional Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

The introduction of temozolomide (TMZ) has improved chemotherapy for malignant gliomas. However, many gliomas are refractory to TMZ, so there is a pressing need for more effective therapeutic options. Here we demonstrated that glioma specimens and cell lines have constitutively high levels of nuclear factor κB (NF-κB) activity. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835183030
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2018.04.033DOI Listing
August 2018
3 Reads

IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme.

Oncotarget 2018 Mar 20;9(23):16462-16476. Epub 2018 Feb 20.

Department of Histology and Embryology, Charles University, Faculty of Medicine in Pilsen, 306 05 Pilsen, Czech Republic.

Introduction: Glioblastoma multiforme (GBM) represents the most malignant primary brain tumor characterized by pathological vascularization. Mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) were observed in GBM. We aimed to assess the intra-tumor hypoxia, angiogenesis and microvessel formation in GBM and to find their associations with IDH1 mutation status and patients prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24536DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893254PMC
March 2018
7 Reads

Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na/K-ATPase α1 subunit.

Biomed Pharmacother 2018 Jul 24;103:204-215. Epub 2018 Apr 24.

Department of Neurosurgery, The Second Affiliated Hospital of Dalian Medical University, 467 Zhong Shan Road, Dalian, 116023, China. Electronic address:

Chansu is a traditional Chinese medicine that is generally recognized as a specific inhibitor of Na/K-ATPase. Bufalin, an active component of Chansu, is an endogenous steroid hormone with great potential as a cancer treatment. However, the mechanism by which it exerts its antitumor activity requires further research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2018.04.030DOI Listing
July 2018
7 Reads

Transcription factor 7 functions as an unfavorable prognostic marker of glioblastoma multiforme by promoting proliferation by upregulating c-Myc.

Neuroreport 2018 06;29(9):745-752

Department of Clinical Laboratory Science, School of Laboratory Medicine, Chengdu Medical College, Chengdu, China.

Transcription factor 7 (TCF7) is an oncogenic transcription factor in several kinds of cancers. However, the clinical significance of TCF7 in glioblastoma multiforme (GBM) has not been well elucidated. A total of 107 patients with surgical resection of GBM were enrolled in our study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNR.0000000000001026DOI Listing

Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature.

Oncol Lett 2018 May 21;15(5):6641-6647. Epub 2018 Feb 21.

Department of Medical Oncology Unit A, Policlinico Umberto I, 'Sapienza' University of Rome, I-00161 Rome, Italy.

Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma that is treated with first-line therapy, using surgical resection followed by local radiotherapy and concomitant/adjuvant temozolomide (TMZ) treatment. GBM is characterised by a high local recurrence rate and a low response to therapy. Primitive neuroectodermal tumour (PNET) of the brain revealed a low local recurrence rate; however, it also exhibited a high risk of cerebrospinal fluid (CSF) dissemination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2018.8102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876436PMC
May 2018
7 Reads

Multicentric Glioblastoma Multiforme Mimicking Optic Neuritis.

Neuroophthalmology 2018 Apr 2;42(2):112-116. Epub 2017 Aug 2.

Department of Radiology, Vittorio Veneto Hospital, Vittorio Veneto, Italy.

A 49-year-old previously healthy woman presented with acute painless visual loss in the right eye, a right relative afferent pupillary defect, and a normal fundus examination. She was diagnosed with retrobulbar "optic neuritis" and given a course of intravenous steroids. Despite treatment, however, she continued to lose vision and serial visual field testing confirmed a junctional scotoma in the fellow eye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/01658107.2017.1350194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858864PMC
April 2018
15 Reads

Tumor Volume Changes During and After Temozolomide Treatment for Newly Diagnosed Higher-Grade Glioma (III and IV).

World Neurosurg 2018 Jun 16;114:e766-e774. Epub 2018 Mar 16.

Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan. Electronic address:

Background: A standard post-concomitant radiochemotherapy involving adjuvant temozolomide (TMZ) was stopped after 6 cycles for high-grade gliomas (HGG). Several studies demonstrated that prolonged TMZ treatment increased survival for these patients.

Methods: This retrospective study aimed to compare changes in tumor volume during and after adjuvant TMZ treatment and overall survival (OS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.03.078DOI Listing
June 2018
5 Reads

An Examination of the Role of Supramaximal Resection of Temporal Lobe Glioblastoma Multiforme.

World Neurosurg 2018 Jun 16;114:e747-e755. Epub 2018 Mar 16.

Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA. Electronic address:

Background: Resection of the T1 contrast-enhancing portion of glioblastoma multiforme (GBM) has been shown to increase patient survival, although whether GBM resection beyond these boundaries has an additional survival benefit is not clear. In this study, we examined the effect of resecting the enhancement and a margin of brain tissue surrounding the enhancement in patients with GBM of the temporal lobe.

Methods: We identified 32 consecutive patients with temporal lobe GBM who underwent initial resection between 2012 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.03.072DOI Listing
June 2018
1 Read